A novel Phase 2 double-blind, randomized, controlled clinical trial to evaluate the efficacy of centrally acting, non-toxic ACE inhibition in cognitive impairment associated with SLE

First posted July, 2020, Updated November, 2021; Recruiting CATEGORIES: CNS Lupus This research study is being done to test the effects of centrally-acting ACE inhibitor, named lisinopril, on resting metabolism in the brain and on cognitive function. The investigators will see if Lisinopril will decrease resting metabolism in the brain and improve cognitive function (memory …

Read More

Study of Ravulizumab in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)

First posted September, 2020, Updated September, 2021; Recruiting CATEGORIES: Lupus Nephritis The objectives of this Phase 2, Double-Blind, Randomized, Placebo-Controlled Study is to evaluate the efficacy and safety of ravulizumab in adult participants With proliferative lupus nephritis (LN) or immunoglobulin A nephropathy (IgAN) To Learn More Contact Contact: Alexion Pharmaceuticals, Inc.at 855-752-2356 or clinicaltrials@alexion.com ClinicalTrials.gov identifier: …

Read More

COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders

CATEGORIES: General SLE This randomized, multi-site, adaptive, open-label clinical trial will compare the immune response to different COVID-19 vaccine booster doses in participants with autoimmune disease requiring immunosuppressive medications. To Learn More Contact Judith A. James, MD, PhD, Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation Meggan C. Mackay, MD, MS, Center of Autoimmune …

Read More

Study of Safety, Efficacy and Tolerability of Secukinumab Versus Placebo, in Combination With SoC Therapy, in Patients With Active Lupus Nephritis (SELUNE)

The purpose of this trial is to evaluate the efficacy and safety of subcutaneous secukinumab 300 mg compared to placebo, in combination with standard of care therapy (SoC), in subjects with active lupus nephritis (ISN/RPS Class III or IV, with or without co-existing class V features). To Learn More Contact Novartis Pharmaceuticals at 1-888-669-6682 or …

Read More

A Study to Evaluate the Efficacy and Safety of BIIB059 in Adult Participants With Active Systemic Lupus Erythematosus Receiving Background Nonbiologic Lupus Standard of Care (TOPAZ-1

First filed May 2021; Recruiting The primary objective of this Phase 3 randomized, double-blind, placebo-controlled study is to test the efficacy of BIIB059 compared with placebo in participants with active systemic lupus erythematosus (SLE), who are receiving background lupus standard of care (SOC) therapy in reducing disease activity. This study is being offered at 20 LuCIN …

Read More

A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus (PHOENYCS GO)

CATEGORIES: General SLE The purpose of this study is to evaluate the ability of dapirolizumab pegol (DZP) as an add-on treatment to standard of care (SOC) medication to achieve clinically relevant long term improvement of moderate to severe disease activity. To Learn More Contact: Contact: UCB Cares  +1844599 ext 2273  UCBCares@ucb.com ClinicalTrials.gov Identifer: NCT04294667 …

Read More

A Study To Evaluate The Efficacy And Safety Of Obinutuzumab In Patients With ISN/RPS 2003 Class III Or IV Lupus Nephritis (REGENCY)

CATEGORIES: Lupus Nephritis The purpose of this study is to determine if AMG 570 could be a useful therapeutic agent in the current treatment landscape where subjects with systemic lupus erythematosus (SLE) have ongoing disease activity despite treatment with standard of care therapies. To Learn More Contact Reference Study ID Number: CA41705 www.roche.com/about_roche/roche_worldwide.htm 888-662-6728 (U.S. …

Read More

Sign up for our Newsletter

Use this tool to search all lupus trials and create a personalized list of studies by the type of lupus you have and where you live.

Sign up